Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,086 matching trials from the local directory fallback.

Filters: Dallas, Texas Clear all

Conditions: Dystonia, Dystonia 10, Dystonia 11, Dystonia 12, Dystonia 19, Dystonia 20, Dystonia 5, Dystonia 6, Dystonia 8, Dystonia 9, Dystonia Disorder, Dystonia Lenticularis, Dystonia of Head, Dystonia, Diurnal, Dystonia, Familial, Dystonia, Focal, Dystonia, Paroxysmal, Dystonia, Primary, Dystonia, Secondary, Dystonia; Idiopathic, Dystonia; Orofacial, Dystonias, Sporadic
Interventions: Magnetic Resonance Imaging; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 11 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity, Overweight
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 41
States / cities: Tuscaloosa, Alabama • Scottsdale, Arizona • Escondido, California + 37 more

Conditions: Smoking
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Rogers, Arkansas • DeLand, Florida • Hollywood, Florida + 15 more

Conditions: Prostate Cancer
Interventions: AAA817, Investigators choice of SoC; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 35
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Colorectal Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma
Interventions: Daraxonrasib, Elironrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Breast Cancer
Interventions: Nanomechanical Phenotype Test; Diagnostic Test
Lead sponsor: ARTIDIS AG; Industry
Eligibility: 18 Years and older
Enrollment: 2,706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Seattle, Washington

Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Ventricular Arrhythmia
Interventions: Catheter ablation; Device
Lead sponsor: Heart Rhythm Clinical and Research Solutions, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 64 more

Conditions: Adolescent, Depression, Emotional Dysregulation, Family Relationship, HRV
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 18 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alcohol Use Disorder
Interventions: Placebo, Semaglutide; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 622 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 19
States / cities: Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more

Conditions: Acute Ischemic Stroke
Interventions: JX10, Placebo; Drug
Lead sponsor: Corxel Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Health-Related Behavior, Healthy Lifestyle
Interventions: Strategic Memory Advanced Reasoning Training teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance; Behavioral
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 22 Years to 100 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Duarte, California • Irvine, California • La Jolla, California + 5 more

Conditions: End Stage Kidney Disease
Interventions: CSL300, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 166
States / cities: Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more

Conditions: Influenza, Human
Interventions: Licensed Influenza Vaccine, mRNA Seasonal Flu vaccine; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 54,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 161
States / cities: Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more

Conditions: Alzheimer's Disease
Interventions: ABBV-1758, Placebo for ABBV-1758; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Irvine, California • Boulder, Colorado • Bradenton, Florida + 8 more

Conditions: Stargardt Disease
Interventions: ALK-001, Placebo; Drug
Lead sponsor: Alkeus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 11 more

Conditions: Suicide, Suicide Attempt
Interventions: Text-messaging for safety reminders, Text-messaging with safety reminders and risk framing; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 13 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Proliferative Diabetic Retinopathy (PDR)
Interventions: Endolaser, Faricimab, Panretinal Photocoagulation (PRP), Vitrectomy; Device · Drug · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 34
States / cities: Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab Injection, Pembrolizumab Injection; Biological
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 97
States / cities: Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more

Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Interventions: WATCHMAN device; Device
Lead sponsor: Hamilton Health Sciences Corporation; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 53
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Fountain Valley, California + 48 more

Conditions: Advanced Solid Tumors, CRC, Colorectal Cancer (CRC), Lung Cancer (NSCLC), NSCLC, Non-small Cell Lung Cancer (NSCLC), PDAC, Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: RMC-5127, cetuximab, daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin Alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 57
States / cities: Arcadia, California • Covina, California • Los Angeles, California + 44 more

Conditions: Status Epilepticus
Interventions: Levetiracetam (LEV) (60 mg/Kg), Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET); Drug
Lead sponsor: University of Virginia; Other
Eligibility: 1 Year and older
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 63
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more

Conditions: Hemorrhagic Shock, Trauma Injury
Interventions: Component Therapy (CT), Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA); Biological · Drug
Lead sponsor: Philip Spinella; Other
Eligibility: Up to 17 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more

Search by objective public record fields.

Dystonia Genotype-Phenotype Correlation

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

Parent-Adolescent Relationships, Emotional Regulation, and HRV in Adolescents With Depression

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Exploring Neurophysiological Markers of Brain Health

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

Study of ALK-001 on the Progression of Stargardt Disease

Nudging Parental Actions for Youth Suicide Prevention

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

The Fourth Left Atrial Appendage Occlusion Study

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children